SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

SAN

77.13

+3.47%↑

ARGX

729.2

+2.76%↑

SHL.DE

34.85

+2.56%↑

PHIA

22.76

+3.41%↑

FRE

37.2

+1.89%↑

Home・Akciju saraksts・Genfit

Genfit

Atvērts

SektorsVeselības aprūpe

9.64 10.05

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.58

Max

9.74

Galvenie mērījumi
By Trading Economics
Ienākumi	-66M -76M
Pārdošana	-3.6M 32M
EPS	-1.525
Peļņas marža	-237.939
Darbinieki	188
EBITDA	-8M -7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+75.44% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	53M 426M
Iepriekšējā atvēršanas cena	-0.41
Iepriekšējā slēgšanas cena	9.64

Ziņu noskaņojums

By Acuity

48%

52%

152 / 344 Rangs Healthcare

Genfit Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūn. 21:51 UTC

Galvenie tirgus virzītāji

Merlin Shares Rally After Defense Department's Design Review Wraps

2026. g. 4. jūn. 23:46 UTC

Tirgus saruna

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026. g. 4. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 4. jūn. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026. g. 4. jūn. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia to Enter Trading Halt

2026. g. 4. jūn. 23:34 UTC

Tirgus saruna

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 4. jūn. 23:08 UTC

Tirgus saruna

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026. g. 4. jūn. 22:41 UTC

Tirgus saruna

Australia Shares Set to Rise at the Open -- Market Talk

2026. g. 4. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026. g. 4. jūn. 20:16 UTC

Tirgus saruna

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026. g. 4. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026. g. 4. jūn. 19:46 UTC

Tirgus saruna

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026. g. 4. jūn. 19:38 UTC

Tirgus saruna

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026. g. 4. jūn. 19:30 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026. g. 4. jūn. 18:47 UTC

Iegādes, apvienošanās, pārņemšana

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026. g. 4. jūn. 18:38 UTC

Peļņas

Money Quote: Tech Weakness in Context -- WSJ

2026. g. 4. jūn. 18:24 UTC

Peļņas

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 17:09 UTC

Tirgus saruna

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026. g. 4. jūn. 16:58 UTC

Peļņas

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 16:46 UTC

Tirgus saruna

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026. g. 4. jūn. 16:38 UTC

Peļņas

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 4. jūn. 16:13 UTC

Tirgus saruna

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026. g. 4. jūn. 16:11 UTC

Tirgus saruna

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026. g. 4. jūn. 15:56 UTC

Tirgus saruna

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Genfit Prognoze

Cenas mērķis

By TipRanks

75.44% augšup

Prognoze 12 mēnešiem

Vidējais 15.001 EUR 75.44%

Augstākais 15 EUR

Zemākais 15 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Genfit — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Genfit — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

152 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.